Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA3Ag vaccine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SA3Ag is an investigational vaccine designed to prevent infections caused by *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA). The vaccine contains three antigens: capsular polysaccharide serotype 5 (*Staphylococcus aureus* capsular polysaccharide type 5) and capsular polysaccharide serotype 8 (*Staphylococcus aureus* capsular polysaccharide type 8), each conjugated to a nontoxic mutant form of diphtheria toxin (CRM197), and a recombinant surface-expressed MSCRAMM protein, clumping factor A (ClfA). These components are intended to induce robust antibody responses that promote opsonophagocytic killing of *S. aureus*. Developed for use in healthy adults, including older populations, the SA3Ag vaccine has demonstrated good immunogenicity and safety in early-phase clinical trials[1][2][4][5]. Pfizer is responsible for its clinical development following acquisition of Wyeth, which had previously licensed the MSCRAMM protein platform from Inhibitex[6].
- Other names
- 3-antigen Staphylococcus aureus vaccine
02
Targets
CP5 (Staphylococcus aureus capsular polysaccharide type 5)CP8 (Staphylococcus aureus capsular polysaccharide type 8)ClfA (Clumping factor A)
Beyond the preview
Go deeper on SA3Ag vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA3Ag vaccine.